image
Healthcare - Drug Manufacturers - General - NYSE - US
$ 15.03
-1.83 %
$ 3.87 B
Market Cap
3.04
P/E
1. INTRINSIC VALUE

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis.[ Read More ]

The intrinsic value of one OGN stock under the base case scenario is HIDDEN Compared to the current market price of 15 USD, Organon & Co. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart OGN

image
FINANCIALS
6.26 B REVENUE
1.44%
1.33 B OPERATING INCOME
-10.08%
1.02 B NET INCOME
11.56%
799 M OPERATING CASH FLOW
-6.88%
-260 M INVESTING CASH FLOW
38.10%
-569 M FINANCING CASH FLOW
-31.41%
1.58 B REVENUE
-1.56%
390 M OPERATING INCOME
1.04%
-395 M NET INCOME
-202.69%
-407 M OPERATING CASH FLOW
-122.73%
142 M INVESTING CASH FLOW
408.22%
-78 M FINANCING CASH FLOW
41.79%
Balance Sheet Decomposition Organon & Co.
image
Current Assets 4.51 B
Cash & Short-Term Investments 693 M
Receivables 1.74 B
Other Current Assets 2.07 B
Non-Current Assets 7.55 B
Long-Term Investments 0
PP&E 1.18 B
Other Non-Current Assets 6.37 B
Current Liabilities 2.92 B
Accounts Payable 1.31 B
Short-Term Debt 9 M
Other Current Liabilities 1.6 B
Non-Current Liabilities 9.21 B
Long-Term Debt 8.88 B
Other Non-Current Liabilities 334 M
EFFICIENCY
Earnings Waterfall Organon & Co.
image
Revenue 6.26 B
Cost Of Revenue 2.52 B
Gross Profit 3.75 B
Operating Expenses 2.42 B
Operating Income 1.33 B
Other Expenses 306 M
Net Income 1.02 B
RATIOS
59.84% GROSS MARGIN
59.84%
21.22% OPERATING MARGIN
21.22%
16.33% NET MARGIN
16.33%
-1461.43% ROE
-1461.43%
8.48% ROA
8.48%
23.25% ROIC
23.25%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Organon & Co.
image
Net Income 1.02 B
Depreciation & Amortization 236 M
Capital Expenditures -261 M
Stock-Based Compensation 101 M
Change in Working Capital -155 M
Others 203 M
Free Cash Flow 538 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Organon & Co.
image
Wall Street analysts predict an average 1-year price target for OGN of $24 , with forecasts ranging from a low of $24 to a high of $24 .
OGN Lowest Price Target Wall Street Target
24 USD 59.68%
OGN Average Price Target Wall Street Target
24 USD 59.68%
OGN Highest Price Target Wall Street Target
24 USD 59.68%
4. DIVIDEND ANALYSIS
1.50% DIVIDEND YIELD
0.28 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Organon & Co.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
49.9 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
8 months ago
Feb 22, 2024
Bought 49.9 K USD
Weaver Kirke
Gen. Counsel & Corp. Secy.
+ 2720
18.3599 USD
3 years ago
Aug 19, 2021
Bought 101 K USD
Francisco Ma. Fatima
Director
+ 3000
33.79 USD
7. News
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 2 days ago
Organon: 7% Yield, 4x P/E, Big Upside Potential Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has shown steady performance with growth in adjusted EBITDA and free cash flow. The acquisition of Dermavant and its promising treatment VTAMA for psoriasis and atopic dermatitis could be transformative, expanding OGN's reach into high-demand areas. seekingalpha.com - 3 days ago
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth more than offsetting pricing weakness and currency headwinds. The $1.2 billion Dermavant acquisition appears strategically acceptable but carries significant risks due to market competition and OGN's high debt. seekingalpha.com - 4 days ago
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. zacks.com - 1 week ago
Organon & Co. (OGN) Q3 2024 Earnings Call Transcript Organon & Co. (NYSE:OGN ) Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Mandeep and I'll be your operator today. seekingalpha.com - 2 weeks ago
Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 2 weeks ago
Organon (OGN) Q3 Earnings and Revenues Beat Estimates Organon (OGN) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.87 per share a year ago. zacks.com - 2 weeks ago
Organon Reports Results for the Third Quarter Ended September 30, 2024 JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Q3 2024 Earnings. businesswire.com - 2 weeks ago
Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics Evaluate the expected performance of Organon (OGN) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 2 weeks ago
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon expands dermatology capabilities through completion of Dermavant acquisition, including nonbiologic, non-steroidal VTAMA Cream, 1%. businesswire.com - 2 weeks ago
Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
Want $300 in Dividends Every Month? Invest $20,000 in Each of These 3 Stocks These dividend stocks all pay yields of around 6% and higher. fool.com - 3 weeks ago
8. Profile Summary

Organon & Co. OGN

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 3.87 B
Dividend Yield 1.50%
Description Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Contact 30 Hudson Street, Jersey City, NJ, 07302 https://www.organon.com
IPO Date May 14, 2021
Employees 10000
Officers Mr. Aaron Falcione Executive Vice President & Chief Human Resources Officer Ms. Rachel A. Stahler Executive Vice President & Chief Information Officer Ms. Jennifer Halchak Head of Investor Relations Ms. Susan O'Neal Chief Ethics & Compliance Officer Mr. Kirke Weaver Executive Vice President, General Counsel & Corporate Secretary Ms. Susanne Gabriele Fiedler Executive Vice President & Chief Commercial Officer Ms. Rebecca Lowell Edwards Chief Communications Officer Mr. Daniel Karp Executive Vice President of Corporate Development Mr. Joseph T. Morrissey Jr. Executive Vice President and Head of Manufacturing & Supply Mr. Kevin Ali Chief Executive Officer & Director